Hyperliquid Strategies (NASDAQ:PURR) Announces Earnings Results

Hyperliquid Strategies (NASDAQ:PURR – Get Free Report) released its earnings results on Thursday. The company reported $2.54 earnings per share for the quarter, topping analysts’ consensus estimates of $2.10 by $0.44, Zacks reports.

Here are the key takeaways from Hyperliquid Strategies’ conference call:

  • Net asset value rose about 82% to $3.4 billion during the quarter, while the company reported $621 million in net income. Management attributed most of the gain to HYPE token appreciation and treasury purchases; its shares were up about 215% since beginning trading.
  • Hyperliquid reported more than $5 trillion in cumulative trading volume and 330,000 monthly unique wallets, and management highlighted its leading position in perpetual DEX volume and open interest. Executives pointed to potential growth from real-world asset markets and U.S. distribution, while acknowledging the user base remains small compared with major centralized platforms.
  • Management said Hyperliquid generated $834 million in value over the 12 months ended September 30, with about 99% of fees directed to token buybacks; it also cited a new USDC-related revenue arrangement that it expects to support buybacks. The company said $1.4 billion has been used for buybacks since inception.
  • The company is applying to establish a U.S. futures commission merchant (FCM), positioning it as a potential neutral intermediary for Hyperliquid customers. Approval and launch timing are uncertain—the process is early, with management estimating a possible three-to-six-month timeframe—and the build-out could cost a single-digit number of millions of dollars.
  • Quarterly results depended heavily on unrealized gains from HYPE’s price increase, which could reverse if the token declines. The company recorded a $172 million tax provision and a corresponding deferred tax liability, though management said the taxes generally become payable only if HYPE tokens are sold.

Hyperliquid Strategies Trading Down 9.5%

Shares of NASDAQ PURR traded down $0.92 during trading hours on Thursday, reaching $8.77. The stock had a trading volume of 28,182,275 shares, compared to its average volume of 12,186,215. Hyperliquid Strategies has a 52-week low of $3.01 and a 52-week high of $14.76. The firm has a market cap of $2.44 billion, a price-to-earnings ratio of -1.37 and a beta of 1.92. The business’s fifty day moving average price is $11.36 and its two-hundred day moving average price is $8.02.

Wall Street Analyst Weigh In

PURR has been the subject of a number of recent analyst reports. Compass Point initiated coverage on shares of Hyperliquid Strategies in a research note on Monday, September 14th. They set a “buy” rating and a $18.00 target price for the company. Wall Street Zen cut shares of Hyperliquid Strategies from a “hold” rating to a “sell” rating in a report on Sunday, October 11th. Cantor Fitzgerald raised their price target on shares of Hyperliquid Strategies from $22.60 to $34.20 and gave the stock an “overweight” rating in a research note on Thursday, September 10th. Weiss Ratings lowered shares of Hyperliquid Strategies from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, October 23rd. Finally, Chardan Capital lifted their price objective on shares of Hyperliquid Strategies from $9.75 to $17.00 and gave the company a “buy” rating in a report on Friday, August 28th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $19.80.

Read Our Latest Analysis on PURR

About Hyperliquid Strategies

(Get Free Report)

Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. Hyperliquid Strategies Inc, formerly known as Sonnet BioTherapeutics Holdings Inc, is based in NEW YORK.

Featured Articles

Receive News & Ratings for Hyperliquid Strategies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperliquid Strategies and related companies with MarketBeat.com's FREE daily email newsletter.